VBCG
NVO

Valley Brook Capital Group’s Novo Nordisk NVO Stock Holding History

Valley Brook Capital Group’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-600
Closed -$20K – 311
2021
Q1 		$20K Hold
600
– – 0.02% 309
2020
Q4 		$20K Buy
+600
New +$20.7K 0.02% 282

Other funds holding NVO

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
State Farm Mutual Automobile Insurance
State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return
EHC
Everett Harris & Co Los Angeles, California $7.77B AUM 9.43% 1-Year Est. Return

Valley Brook Capital Group's NVO Position: Q2 2021 in Review

Valley Brook Capital Group sold out of Novo Nordisk (NVO) in Q2 2021, closing a stake of 600 shares — an estimated $20K sold.

Valley Brook Capital Group first reported a position in NVO in Q4 2020 and held it in 2 quarters. The position peaked at $20K in Q1 2021. 735 funds tracked by Wall St. Rank hold NVO as of Q2 2021.

  • Valley Brook Capital Group reported no remaining Novo Nordisk position as of Q2 2021 after selling out during the quarter.
  • Valley Brook Capital Group sold 600 Novo Nordisk shares in Q2 2021, an estimated $20K.
  • Valley Brook Capital Group first reported a position in Novo Nordisk in Q4 2020 and held it in 2 quarters.
  • Valley Brook Capital Group's Novo Nordisk position peaked at $20K in Q1 2021.
  • 735 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2021.

Based on Valley Brook Capital Group's 13F filing for Q2 2021, filed 22 Jul 2021.